Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ajanta PharmaNSE:AJANTPHARM -0.66%95 EBITDA Margin % is 30.41% as of Jun. 2026, which is 1% above its 10-year median of 30.16. GuruFocus rates NSE:AJANTPHARM with a GF Score™ of 95/100 and a GF Value™ of ₹3,348.50 (Fairly Valued). The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Ajanta Pharma ranks better than 85.09% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Ajanta Pharma's EBITDA for the
three
months ended in Jun. 2026 was ₹4,945 Mil. Ajanta Pharma's Revenue for the
three
months ended in Jun. 2026 was ₹16,260 Mil. Therefore, Ajanta Pharma's EBITDA margin for the quarter that ended in Jun. 2026 was 30.41%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Ajanta Pharma EBITDA Margin % Related Terms
Ajanta Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Ajanta Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ajanta Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Ajanta Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ajanta Pharma (NSE:AJANTPHARM) has a EBITDA Margin % of 30.41% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ajanta Pharma and its competitors. This is near median its historical median of 30.16. Over the past decade, Ajanta Pharma's EBITDA Margin % has ranged from 23.79 to 37.09. According to the industry distribution chart, Ajanta Pharma ranks #143 out of 959 companies in the Drug Manufacturers industry, placing it in the top 14.9%.
Is Ajanta Pharma's EBITDA Margin % too high?
Ajanta Pharma's current EBITDA Margin % of 30.41% is near median its 10-year median of 30.16. Over the past 10 years, this metric has ranged from a low of 23.79 to a high of 37.09. The Drug Manufacturers industry median EBITDA Margin % is 11.89. Ajanta Pharma's value of 30.41% is 155.8% above this industry median. Based on the distribution chart, Ajanta Pharma ranks #143 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ajanta Pharma has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ajanta Pharma's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ajanta Pharma ranks #143 out of 959 companies for EBITDA Margin %. This places Ajanta Pharma in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 11.89. Ajanta Pharma's value of 30.41% is 155.8% above this benchmark. Historically, Ajanta Pharma's own EBITDA Margin % has ranged from 23.79 to 37.09 over the past decade. While the company's 10-year median is 30.16 vs. the industry median of 11.89, Ajanta Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 11.89, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ajanta Pharma's current EBITDA Margin % of 30.41% is 155.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Ajanta Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 11.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ajanta Pharma's current EBITDA Margin % is 30.41%, which is near median its own 10-year median of 30.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ajanta Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ajanta Pharma (NSE:AJANTPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹3,348.50, compared to a current price of ₹3,481.70 — trading 4% above its estimated fair value. The current EBITDA Margin % is 30.41%, which is near median its 10-year median of 30.16 and 155.8% above the Drug Manufacturers industry median of 11.89. Ajanta Pharma's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Ajanta Pharma (NSE:AJANTPHARM), the current EBITDA Margin % is 30.41% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ajanta Pharma (NSE:AJANTPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Ajanta Pharma stock appears to be overvalued.
The current stock price of ₹3,481.70 is trading 4% above its estimated GF Value™ of ₹3,348.50.
GuruFocus considers Ajanta Pharma to be Fairly Valued.
Key valuation signals for NSE:AJANTPHARM:
EBITDA Margin %: 30.41% (near median its 10-year median of 30.16)
GF Value™: ₹3,348.50 vs. price of ₹3,481.70 (4% above fair value)
Industry Position: 155.8% above the Drug Manufacturers median (#143 of 959)
No single metric tells the full story. See the NSE:AJANTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ajanta Pharma Ltd is mainly involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages. The operations of the Group are limited to only one segment viz. pharmaceuticals and related products. The company has presence in India, Emerging Market, Africa Institution, and USA. The company generates majority of revenue from Emerging market.
95GF Score
Get the complete analysis for NSE:AJANTPHARM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AJANTPHARM has been successfully added to your 
